← Search another drug
PatientPulse · by PatientPartner
Xarelto rivaroxaban
High confidence
~56 public patient conversations and reviews analyzed (forums, blogs, review sites, and patient community pages)
Executive intelligence
The signal that moves starts & adherence
32%Positive sentiment in discussion
205,037FDA adverse-event reports
84%Flagged serious
50%Reports name female patients
The single biggest commercial risk is unsupported self-discontinuation: patients who feel dismissed by their physicians stop Xarelto unilaterally, creating a thrombotic rebound hazard that peer mentorship and proactive side-effect counseling could directly prevent.
- Side-effect dismissal by prescribers is the dominant adherence leak: patients who report musculoskeletal pain, fatigue, or neurological symptoms are routinely told the drug cannot be the cause, pushing them toward unsupported discontinuation.
- Cost is a rising friction point across all age groups, with Medicare Part D patients confused by the gap between negotiated prices and actual copays, and the 2025 generic approval creating new switching conversations cardiologists are unprepared for.
- The no-antidote concern has faded from the top of patient anxiety relative to lived side-effect burden, but it resurfaces acutely around surgical procedures, where bridging confusion drives ER visits.
- A meaningful subpopulation of long-term users questions ongoing necessity once their primary trigger (AF conversion, DVT resolution) is resolved, representing a structured deprescribing conversation gap for the care team.